Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.45 |
| ▸ | TDP2 | O95551 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481109 | 0.92 | MAP3K5 (0.51) | MAP3K5CYP11B2CYP11B1TDP2CYP1A2 | |
| SCHEMBL13113578 | 0.89 | TNF (0.44) | MAP3K5FAAHLRRK2MCHR1 | |
| SCHEMBL13872207 | 0.88 | CYP11B1 (0.43) | MAP3K5CYP11B2CYP11B1TDP2CYP1A2 | |
| SCHEMBL13113354 | 0.87 | MCHR1 (0.48) | MAP3K5MEN1TP53CYP3A4CYP2D6 | |
| SCHEMBL13113767 | 0.83 | MAP3K5 (0.54) | MAP3K5CYP11B2CYP11B1TDP2CYP1A2 | |
| SCHEMBL13113595 | 0.81 | TNF (0.44) | MAP3K5CYP11B2LRRK2MCHR1 | |
| SCHEMBL13113563 | 0.81 | NPC1 (0.49) | KDM4EMEN1RECQLKMT2ATDP1 | |
| SCHEMBL13113409 | 0.79 | MCHR1 (0.48) | MAP3K5MEN1TP53CYP3A4CYP2D6 | |
| SCHEMBL13871907 | 0.79 | MAP3K5 (0.49) | MAP3K5CYP11B2CYP11B1TDP2CYP1A2 | |
| SCHEMBL13113452 | 0.78 | NPC1 (0.47) | KDM4ETP53HTR2BHTR2CMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | MAP3K5 4170/4885CYP11B2 2631/4885CYP11B1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.